Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Krystal Biotech, Inc. (KRYS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 144 Form 144 - Report of proposed sale of securities:
08/21/2023 144 Form 144 - Report of proposed sale of securities:
08/16/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/11/2023 144 Form 144 - Report of proposed sale of securities:
08/10/2023 144 Form 144 - Report of proposed sale of securities:
08/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/07/2023 8-K Quarterly results
Docs: "Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights"
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/26/2023 8-K Quarterly results
07/18/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
06/09/2023 144 Form 144 - Report of proposed sale of securities:
06/08/2023 144 Form 144 - Report of proposed sale of securities:
05/31/2023 144 Form 144 - Report of proposed sale of securities:
05/31/2023 144 Form 144 - Report of proposed sale of securities:
05/23/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/19/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEKTM for the Treatment of Dystrophic Epidermolysis Bullosa",
"Updated Risk Factors"
05/19/2023 144 Form 144 - Report of proposed sale of securities:
05/19/2023 144 Form 144 - Report of proposed sale of securities:
05/11/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "PA BACKGROUND STUDY DESIGN AND METHODS RESULTS DISCUSSION CONCLUSION ACKNOWLEDGEMENTS"
05/10/2023 SC 13G/A FMR LLC reports a 10.1% stake in KRYSTAL BIOTECH INC
05/08/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sales Agreement, by and between Krystal Biotech, Inc. and Cowen and Company, LLC",
"Opinion of Morrison & Foerster LLP"
05/08/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/08/2023 8-K Quarterly results
Docs: "Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights"
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/24/2023 8-K Quarterly results
04/19/2023 144 Form 144 - Report of proposed sale of securities:
04/17/2023 144 Form 144 - Report of proposed sale of securities:
04/17/2023 144 Form 144 - Report of proposed sale of securities:
04/06/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
04/04/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/04/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Krystal Biotech Appoints Catherine Mazzacco to Board of Directors"
02/27/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy